Keynote Lecture: 

Lyn Jones, PhD

Director of the Center for Protein Degradation at Dana-Farber Cancer Institute

Next-Generation Covalent Drug Discovery – Targeting Residues Beyond Cysteine

Keynote Lecture:

John A Porco, Jr., PhD

CMD Director and Professor of Chemistry @ Boston University

Chemical Synthesis of Complex Molecules for Translational Science

Kevin Cottrell, PhD

Executive Director, Medicinal Chemistry @ Tango Therapeutics

MTA-cooperative PRMT5 Inhibitors For the Treatment of MTAP-deleted Cancers

Bernhard Fasching, PhD

Vice President, Chemistry @ Monte Rosa Therapeutics

Rational Discovery and Design of Molecular Glue Degraders

David Griffith, PhD

Research Fellow @ Pfizer

Small Molecule GLP-1 Receptor Agonists Suitable for Once-daily Oral Administration

Eileen Hoang, PhD

Scientist, Process Chemistry @ Sanofi

Sustainability-Driven Science: How Process Chemistry at Sanofi Integrates Eco-Design with Process Development

Hong Myung Lee, PhD

Principal Scientist @ Takeda Pharmaceuticals

Identification of A Novel Linker Enabling Bioconjugation of A Cyclic Dinucleotide For the STING Antibody Drug Conjugate TAK-500

Mike Visser, PhD

Director @ Novartis Institutes for Biomedical Research

Discovery and Characterization of a First-In-Class Selective IKZF2 Glue Degrader for Immuno-Oncology Applications

Matthew Weiss, PhD

Executive Director, Head of Medicinal Chemistry @ Kymera Therapeutics

Discovery of Potent, Orally Bioavailable IRAK4 Degraders for the Treatment of Oncology and Immuno-Inflammatory Diseases

Abba Leffler

Senior Principal Scientist @ Schrodinger

Exploiting High-Energy Hydration Sites for the Discovery of Potent Peptide Aldehyde Inhibitors of the SARS-CoV-2 Main Protease with Cellular Antiviral Activity